Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Declares Quarterly Dividend of $0.94

by · The Cerbat Gem

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) announced a quarterly dividend on Friday, January 30th. Investors of record on Friday, February 20th will be given a dividend of 0.94 per share by the biopharmaceutical company on Thursday, March 5th. This represents a c) annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Friday, February 20th. This is a 6.8% increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88.

Regeneron Pharmaceuticals has a payout ratio of 8.9% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Regeneron Pharmaceuticals to earn $38.02 per share next year, which means the company should continue to be able to cover its $3.52 annual dividend with an expected future payout ratio of 9.3%.

Regeneron Pharmaceuticals Stock Down 1.1%

NASDAQ REGN traded down $7.99 during trading hours on Friday, reaching $741.45. 1,317,463 shares of the company’s stock traded hands, compared to its average volume of 923,102. Regeneron Pharmaceuticals has a 52-week low of $476.49 and a 52-week high of $821.11. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33. The firm has a 50-day simple moving average of $758.68 and a 200 day simple moving average of $648.66. The firm has a market cap of $77.93 billion, a PE ratio of 17.76, a PEG ratio of 1.96 and a beta of 0.39.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the previous year, the company earned $12.07 earnings per share. The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. Sell-side analysts anticipate that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. The trade was a 9.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 46.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 7.02% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Activest Wealth Management raised its holdings in Regeneron Pharmaceuticals by 78.9% in the fourth quarter. Activest Wealth Management now owns 68 shares of the biopharmaceutical company’s stock worth $52,000 after purchasing an additional 30 shares in the last quarter. Simplicity Wealth LLC grew its position in shares of Regeneron Pharmaceuticals by 123.5% in the 4th quarter. Simplicity Wealth LLC now owns 845 shares of the biopharmaceutical company’s stock worth $653,000 after buying an additional 467 shares during the last quarter. Keybank National Association OH raised its stake in shares of Regeneron Pharmaceuticals by 5.9% during the 4th quarter. Keybank National Association OH now owns 1,675 shares of the biopharmaceutical company’s stock worth $1,293,000 after acquiring an additional 94 shares in the last quarter. Westhampton Capital LLC lifted its position in Regeneron Pharmaceuticals by 3.4% during the fourth quarter. Westhampton Capital LLC now owns 1,223 shares of the biopharmaceutical company’s stock valued at $944,000 after acquiring an additional 40 shares during the last quarter. Finally, Oakworth Capital Inc. boosted its stake in Regeneron Pharmaceuticals by 124.0% in the fourth quarter. Oakworth Capital Inc. now owns 56 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 31 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

(Get Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Further Reading